Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Major Trauma Emergency Blood Transfusions Need Consistency

By LabMedica International staff writers
Posted on 16 Feb 2016
Globally, bleeding following injury is estimated to be responsible for over two million deaths per year and current treatment strategies focus on the rapid delivery of red blood cells, plasma and other clotting products.

Nearly 5,000 trauma patients sustain major hemorrhage in England and Wales each year and that one-third of those die and delays in blood transfusion practices may contribute to this high death rate. More...
The logistics of providing the correct quantities in the right proportion during the first minutes and hours of emergency care can be extremely challenging.

A team of scientists led by those at the Queen Mary, University of London (London, UK) carried out a prospective observational study from 22 hospitals in the UK, including both major trauma centers and smaller trauma units. Eligible patients received at least four units of packed red blood cells (PRBCs) in the first 24 hours of admission with activation of the massive hemorrhage protocol. The study outcomes were the use of blood components, critical care during hospital stay, and mortality at 24 hours, 30 days and one year.

Overall, only 2% of all patients with massive hemorrhage received what might be considered the optimal transfusion of a high dose of clotting products in conjunction with red blood cells during the first hour of arrival within the Emergency Department. The average time to transfusion of red blood cells was longer than expected, at 41 minutes. Administration of specific blood components to aid with blood clotting such as plasma, platelets and cryoprecipitate was significantly delayed, occurring on average 2-3 hours after admission.

Mortality from bleeding tended to occur early, with nearly two-thirds of all deaths in the first 24 hours. An unexpectedly high number of deaths (7.9%) occurred once the patient left hospital, the reasons for which were unclear. The incidence of major hemorrhage increased markedly in patients over 65 years, who were twice as likely to suffer massive hemorrhage as a result of an injury compared to younger groups. Patients who received a cumulative ratio of fresh frozen plasma to PRBCs of at least 1:2 had lower rates of death than those who received a lower ratio. There were delays in administration of blood. Platelets and cryoprecipitate were either not given, or transfused well after initial resuscitation.

Karim Brohi, MD, a professor of Trauma Surgery and senior author of the study said, “Bleeding is the leading cause of preventable death in trauma. The rapid and consistent delivery of blood, plasma, platelets and other clotting products to trauma patients is essential to maintain clotting during hemorrhage and has been shown to halve mortality. However, we found that only 2% of patients with massive hemorrhage received the optimal type of blood transfusion for their resuscitation. There is a clear opportunity for clinicians to improve the delivery of blood and clotting products during resuscitation for major hemorrhage.” The study was published on February 3, 2016, in the British Journal of Surgery.

Related Links:

Queen Mary, University of London 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
HPV Molecular Test
BD Onclarity HPV Assay
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.